@article{fdi:010078045,
  title = {{C}omparative immunovirological and clinical responses to antiretroviral therapy between {HIV}-1 {G}roup {O} and {HIV}-1 {G}roup {M} infected patients},
  author = {{K}ouanfack, {C}. and {U}nal, {G}. and {S}chaeffer, {L}. and {K}futwah, {A}. and {A}ghokeng {F}obang, {A}velin and {M}ougnutou, {R}. and {T}chemgui-{N}oumsi, {N}. and {A}lessandri-{G}radt, {E}. and {D}elaporte, {E}. and {S}imon, {F}. and {V}ray, {M}. and {P}lantier, {J}. {C}. and {ANRS} {D}yna{MO} {S}tudy},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground. {L}ittle is known about impact of genetic divergence of human immunodeficiency virus type 1 group {O} ({HIV}-1/{O}) relative to {HIV}-1 group {M} ({HIV}-1/{M}) on therapeutic outcomes. {W}e aimed to determine if responses to standardized combination antiretroviral therapy (c{ART}) were similar between groups despite strain divergence. {M}ethods. {W}e performed an open nonrandomized study comparing the immunological, virological, and clinical responses to c{ART} based on 2 nucleoside reverse transcriptase inhibitors plus 1 ritonavir-boosted protease inhibitor, in naive and paired {HIV}-1/{O} vs {HIV}-1/{M} infected (+) patients (ratio 1:2), matched on several criteria. {T}he primary endpoint was the proportion of patients with undetectable plasma viral load (p{VL}, threshold 60 copies/m{L}) at week ({W}) 48. {S}econdary endpoints were the proportion of patients with undetectable p{VL} at {W}24 and {W}96 and {CD}4 evolution between baseline and {W}24, {W}48, and {W}96. {R}esults. {F}orty-seven {HIV}-1/{O}+ and 94 {HIV}-1/{M}+ patients were included. {M}ean p{VL} at baseline was significantly lower by 1 log for {HIV}-1/{O}+ vs {HIV}-1/{M}+ patients. {A}t {W}48, no significant difference was observed between populations with undetectable p{VL} and differences at {W}24 and {W}96 were not significant. {A} difference in {CD}4 gain was observed in favor of {HIV}-1/{M} at {W}48 and {W}96, but this was not significant when adjusted on both matched criteria and p{VL} at baseline. {C}onclusions. {O}ur data demonstrate similar immunovirological and clinical response between {HIV}-1/{O}+ and {HIV}-1/{M}+ patients. {T}hey also reveal significantly lower baseline replication for {HIV}-1/{O} variants, suggesting specific virological properties and physiopathology that now need to be addressed.},
  keywords = {{HIV}-1 group {O} ; immunovirological response ; genetic diversity ; c{ART}},
  booktitle = {},
  journal = {{C}linical {I}nfectious {D}iseases},
  volume = {70},
  numero = {7},
  pages = {1471--1477},
  ISSN = {1058-4838},
  year = {2020},
  DOI = {10.1093/cid/ciz371},
  URL = {https://www.documentation.ird.fr/hor/fdi:010078045},
}